Kymera Therapeutics, Inc. reported preclinical data highlighting the therapeutic potential in liquid and solid tumors of potent and selective heterobifunctional degraders of MDM2, including KT-253. The data was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 11-15, 2023, in Boston, Massachusetts and will also be shared at the 10th International MDM2 Workshop taking place October 15-18, 2023, in Tokyo, Japan. MDM2 is a crucial regulator of the most common tumor suppressor, p53.

p53 remains intact (wild type) in approximately 50% of cancers, meaning that it retains its ability to modulate cancer cell growth. This may enable an improved therapeutic index, which could result in a superior efficacy and safety profile over MDM2 SMIs. The Company previously presented data on KT-253, its lead MDM2 degrader, showing greater than 200-fold higher growth inhibition potency in vitro against p53 wild-type cancer cell lines compared with MDM2 SMI and a favorable pharmacological profile.

Results shared at the 10th InternationalMDM2 workshop show potent in vivo activity of a single dose of KT-253 in models of AML and ALL as well as activity in combination with clinical and sub-clinical doses of venetoclax in a venetoclax-resistant AML model.